Abstract
Purpose
To review the proportion of diabetic patients reaching recommended therapeutic goals, as reported in intervention trials and observational studies, and to analyse the factors associated with success or failure in achieving these targets.
Methods
A systematic review and meta-analysis through a Medline and Embase search for “diabetes” and “HbA1c” has been performed between 1 January 1995 and 1 March 2012 on randomised clinical trials and observational studies on type 1 (T1DM) or type 2 diabetes (T2DM) enrolling at least 200 patient*year.
Results
Out of 169 patient groups in RCTs with results available for analysis, the overall proportion of patients reaching HbA1c ≤7 % was 36.6 (34.1–39.1) %. Of these, 8 groups included T1DM subjects [proportion at target (PAT) 27.2 (22.7–32.3) %] and 161 T2DM patients [PAT 37.1 (34.5–39.7) %]. In patients with T2DM on oral agents, at multivariate analysis, higher success rate was associated with higher age and body mass index (BMI), lower duration of diabetes, lower proportion of Caucasians and more recent publication year. Among the insulin treated, only duration of diabetes retained a significant association with success rate. Among 41 groups from cross-sectional studies, 6 and 22 were composed of patients with T1DM and T2DM, respectively, and the remaining 13 included both types. Patients at target for HbA1c were 19.8 (12.4–30.1), 36.1 (31.5–41.0), and 39.0 (32.9–45.3) %, respectively. Higher age, lower BMI, shorter duration of diabetes and a higher proportion of males and Caucasians were associated with a higher success rate.
Conclusions
Available data show that a wide distance remains between recommended targets and actual achievements in routine clinical practice.
Similar content being viewed by others
References
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234
Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287(19):2570–2581
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572
Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19(9):604–612
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169
Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379
American Association of Clinical Endocrinologist (2007) Medical guidelines for clinical practice for the management of diabetes mellitus. http://www.aace.com
IDF Clinical Guidelines Task Force (2006) Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 23(6):579–593
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial 17(1):1–12
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdóttir S, Eliasson B, Steering Committee of the Swedish National Diabetes Register (2007) Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 30(3):496–502
Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S (2005) The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996–2003. Diabet Med 22:1420–1426
Bruno G, Merletti F, Bargero G et al (2008) Changes over time in the prevalence and quality of care of type 2 diabetes in Italy: the Casale Monferrato surveys, 1988 and 2000. Nutr Metab Cardiovasc Dis 18:39–45
Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335–342
Ford ES, Li C, Little RR, Mokdad AH (2008) Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 31:102–104
Hovind P, Tarnow L, Rossing K et al (2003) Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258–1264
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859–1868
Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. NEJM 366:1227–1239
Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group (2008) Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study. J Assoc Physicians India 56:859–863
Sharma SK, Al-Mustafa M, Oh SJ, Azar ST, Shestakova M, Guler S, Vaz JA (2008) Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin 24(3):645–652
Hanberger L, Samuelsson U, Lindblad B, Ludvigsson J, Swedish Childhood Diabetes Registry SWEDIABKIDS (2008) A1C in children and adolescents with diabetes in relation to certain clinical parameters: the Swedish Childhood Diabetes Registry SWEDIABKIDS. Diabetes Care 31(5):927–929 (Epub 2008 Jan 30)
Pan CY, Ho LT, Soegondo S, Prodjosudjadi W, Suwanwalaikorn S, Lim SC, Chan TM, Chow KW, Thoenes M, Choi DS, DEMAND Study Investigators (2008) Prevalence of albuminuria and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective. Diabetes Technol Ther 10(5):397–403
Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE (2008) Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 25(4):435–441 Epub 2008 Mar 13
Cheung NW, Conn JJ, d’Emden MC, Gunton JE, Jenkins AJ, Ross GP, Sinha AK, Andrikopoulos S, Colagiuri S, Twigg SM, Australian Diabetes Society (2009) Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 191(6):339–344
Plöckinger U, Topuz M, Langer M, Reuter T (2010) Problems of diabetes management in the immigrant population in Germany. Diabetes Res Clin Pract 87(1):77–86
Kaplan SH, Billimek J, Sorkin DH, Ngo-Metzger Q, Greenfield S (2010) Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care 48(6 Suppl):16 (Diabetes Res Clin Pract. 2006; 73(2):198–204)
Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, Ozaki R, Ma RC, Cockram CS, Chow CC, Chan JC (2008) Use of anti-diabetic drugs and glycaemic control in type 2 diabetes—The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 82(3):346–352
Elis A, Rosenmann L, Chodick G, Heymann AD, Kokia E, Shalev V (2008) The association between glycemic, lipids and blood pressure control among Israeli diabetic patients. QJM 101(4):275–280
Erasmus RT, Blanco Blanco E, Okesina AB, Gqweta Z, Matsha T (1999) Assessment of glycaemic control in stable type 2 black South African diabetics attending a peri-urban clinic. Postgrad Med J 75(888):603–606
Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E (2005) Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28(3):514–520
Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291(3):335–342
McAlister FA, Majumdar SR, Eurich DT, Johnson JA (2007) The effect of specialist care within the first year on subsequent outcomes in 24,232 adults with new-onset diabetes mellitus: population-based cohort study. Qual Saf Health Care 16(1):6–11
Muggeo M, Verlato G, Bonora E et al (1995) The Verona Diabetes Study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia 38:318
Trento M, Gamba S, Gentile L, ROMEO Investigators et al (2010) Rethink Organization to iMprove Education and Outcomes (ROMEO): a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes. Diabetes Care 33(4):745–747
Gill G (2003) Intensified treatment of type 2 diabetes—positive effects on blood pressure, but not glycaemic control. QJM 96:833–836
Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. NEJM 358:2545–2559
Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 348:383–393
Haugstvedt A, Wentzel-Larsen T, Graue M, Søvik O, Rokne B (2010) Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med 27(1):72–78
Drew LM, Berg C, King P et al (2011) Depleted parental psychological resources as mediators of the association of income with adherence and metabolic control. J Fam Psychol 25(5):751–758
Reach G, Michault A, Bihan H et al (2011) Patients’ impatience is an independent determinant of poor diabetes control. Diabetes Metab 37:497–504
Reach G (2011) Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients. Patient Prefer Adherence 5:523–531
Hirsch IB, Brownlee M (2010) Beyond haemoglobin A1c—need for additional markers of risk for diabetic microvascular complications. JAMA 303:2291–2292
Hemmingsen B, Lund SS, Gluud C et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898
Standards of Medical Care in Diabetes (2012) Diabetes Care 35:S11–S63
Conflict of interest
Authors declare no conflicts of interest that might bias their work.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mannucci, E., Monami, M., Dicembrini, I. et al. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Invest 37, 477–495 (2014). https://doi.org/10.1007/s40618-014-0069-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-014-0069-6